James N Kochenderfer
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
11
all conditions, ClinicalTrials.gov
NIH grants tied to them
7
NIH RePORTER
Trial papers
13
PubMed author-name match
Trials
Studies that name James N Kochenderfer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:55 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06904066 · Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNational Cancer Institute (NCI) · recruiting · Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic · principal investigator
- Ph1/Ph2NCT06364423 · Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for LeukemiasNational Cancer Institute (NCI) · recruiting · Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT05797233 · Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell MalignanciesNational Cancer Institute (NCI) · active not recruiting · Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell · principal investigator
- Ph1NCT04160195 · T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin LymphomaNational Cancer Institute (NCI) · terminated · Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT03958656 · T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple MyelomaNational Cancer Institute (NCI) · completed · Myeloma-Multiple, Myeloma, Plasma-Cell · principal investigator
- Ph1NCT03602612 · T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple MyelomaNational Cancer Institute (NCI) · completed · Myeloma-Multiple, Myeloma, Plasma-Cell · principal investigator
- Ph1NCT03049449 · T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing LymphomasNational Cancer Institute (NCI) · completed · Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse · principal investigator
- Ph1NCT02659943 · T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesNational Cancer Institute (NCI) · completed · Lymphoma, B-Cell, Lymphoma, Non-hodgkins · principal investigator
- N/ANCT02473757 · Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell StudiesNational Cancer Institute (NCI) · enrolling by invitation · Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma · principal investigator
- Ph1NCT02215967 · Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple MyelomaNational Cancer Institute (NCI) · completed · Myeloma, Plasma-Cell, Myeloma-Multiple · principal investigator
- Ph1NCT01087294 · Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell TransplantationNational Cancer Institute (NCI) · completed · Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Adoptive T-cell Therapies Targeting Mutations in Hematologic MalignanciesZIABC012158 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2023 to 2025 · $693,831 awarded in 2025Same name and institution; not confirmed by an ID
- Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen ReceptorZIABC011415 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2011 to 2025 · $138,766 awarded in 2025Same name and institution; not confirmed by an ID
- Development of CAR T cells targeting T-cell malignanciesZIABC012157 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2023 to 2025 · $693,831 awarded in 2025Same name and institution; not confirmed by an ID
- Development of Chimeric Antigen Receptors Targeting Multiple MyelomaZIABC011439 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2012 to 2025 · $693,831 awarded in 2025Same name and institution; not confirmed by an ID
- Improved Chimeric Antigen Receptor Therapies B-cell MalignanciesZIABC011417 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2011 to 2025 · $555,064 awarded in 2025Same name and institution; not confirmed by an ID
- Development of fully-human anti-CD30 chimeric antigen receptorsZIABC011660 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2015 to 2023 · $156,091 awarded in 2023Same name and institution; not confirmed by an ID
- Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen ReceptorZIABC011413 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2011 to 2016 · $244,768 awarded in 2016Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:55 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- 2,446 citationsRCR 71.3
- 1,433 citationsRCR 50.4
- 1,327 citationsRCR 38.4
- 1,207 citationsRCR 28.9
- 1,086 citationsRCR 22.1
- 679 citationsRCR 20.2
- 505 citationsRCR 12.7
- 281 citationsRCR 7.8
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Nat Med · 2020271 citationsRCR 10.0
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.J Clin Oncol · 2020259 citationsRCR 9.5